Core Framework & Diagram What Is Immune Nanotechnology?
July 23, 20261 Min Read What Is Immune AI?
July 23, 2026Delivering the immune system's weapons precisely inside 'delivery boxes' a thousand times smaller than a cell
—— Immune Nanotechnology: from the lipid nanoparticles of mRNA vaccines to nanoparticle immune warriors targeting tumors.
I. LNP: the technological milestone that saved mRNA vaccines
mRNA is a chemically extremely unstable molecule. After injection into the body, large amounts of ribonuclease (RNase) in blood will degrade it within minutes to hours. Additionally, mRNA is a large negatively charged molecule, and cell membranes are negatively charged lipid bilayers — same-charge repulsion means bare mRNA can almost never independently enter cells. Lipid Nanoparticles (LNP) solved both problems: physical protection (LNP's lipid outer shell wraps mRNA, isolating it from blood's degradation enzymes); and cell entry (ionizable lipids on LNP surface become positively charged in the acidic endosome environment after cell uptake via endocytosis, electrostatically interacting with the endosome membrane, promoting mRNA escape from the endosome into the cytoplasm, completing 'the last mile of delivery').
LNP's core patents were developed by Pieter Cullis's team at the University of British Columbia, later adopted by Moderna and BioNTech for COVID vaccines. This nanotechnology is what took mRNA vaccines from lab to billions of people globally. LNP's success also opened the entire mRNA therapeutics field — not just vaccines, but mRNA tumor vaccines, mRNA protein replacement therapies (like mRNA encoding missing clotting factors for hemophilia), and mRNA gene editing tools (like Cas9's mRNA form) all depend on LNP-class delivery technology.
|
LNP is immune nanotechnology's most successful commercial product. Without it, mRNA vaccines are a delivery that can't complete 'the last mile' — no matter how good the cargo, if it can't reach the door, it has no value. |
2. Nanoparticles targeting tumor microenvironments: precision 'battlefield transformation'
The previous article (135) discussed various immune microenvironment engineering strategies, but these strategies all face a common problem: how to precisely deliver transformation tools to the tumor microenvironment? Nanotechnology is precisely the technical answer to this question. Nanoparticles targeting tumor microenvironments can exploit tumor tissue's special physical-chemical characteristics (EPR effect — enhanced permeability and retention effect; tumor's acidic pH; specific receptor expression) to actively or passively accumulate in the tumor microenvironment, precisely releasing transformation tools.
Representative applications: nanoparticles targeting M2 macrophages — surface-modified with ligands targeting M2-specific receptors (like mannose receptor CD206), carrying M1 polarization inducers (like IL-12 mRNA or toll-like receptor agonists), selectively reprogramming M2-type tumor-associated macrophages to M1 type, locally changing tumor immune cell polarity without affecting systemic immunity; nanoparticles targeting CAFs — using FAP (fibroblast activation protein) as a target, nanoparticles surface-modified with FAP antibody fragments selectively delivering matrix-softening enzymes, breaking the tumor's physical barriers; adenosine pathway blocking nanoparticles — carrying A2AR antagonists, entering tumors to relieve adenosine's 'anesthetic effect' on NK cells and T cells.
3. CRISPR delivery: gene editing's 'delivery box'
CRISPR gene editing technology needs to precisely deliver Cas9 protein and guide RNA (gRNA) into target cells' nuclei to function — one of the most difficult technical challenges in CRISPR's in vivo application. Nanoparticles are becoming CRISPR's main in vivo delivery vehicles: LNP-CRISPR — encapsulating Cas9 mRNA (or Cas9 ribonucleoprotein RNP) and gRNA in LNP, similar logic to mRNA vaccine delivery, but aimed at entering cell nuclei to complete gene editing. In 2023, LNP-CRISPR therapy (Intellia Therapeutics' NTLA-2001) in clinical trials for transthyretin cardiomyopathy (TTR cardiomyopathy) achieved liver-targeted CRISPR editing in the human body, with TTR protein levels decreasing by up to eighty-seven percent — a milestone result for in vivo CRISPR treatment.
Lipid nanoparticles targeting T cells — recent research (especially Michael Mitchell's team at University of Pennsylvania) developed LNP formulations specifically targeting T cells, capable of directly delivering CAR genes or CRISPR editing tools to T cells in the body, achieving 'in vivo CAR-T' — no longer needing to take T cells from patients for ex vivo modification, instead directly injecting LNP carrying CAR genes to complete T cell modification in the body. 'In vivo CAR-T' (In vivo CAR-T), if successful, would completely change CAR-T therapy's production model — from weeks of individualized ex vivo manufacturing to a universal injectable that can be given immediately, dramatically reducing costs and greatly improving accessibility.
4. Biomimetic nanoparticles: wearing cells' 'outer clothing'
One major challenge for nanoparticles in the body is the immune system recognizes them as 'foreign objects' and through opsonization marks them for clearance by macrophages. Biomimetic Nanoparticles use real cells' membranes to coat nanoparticle cores, giving them cells' 'invisible' capability and targeting: red blood cell membrane coating (RBC-NP) — red blood cells are the body's longest-lived cells (~120 days), partly because their surfaces have large amounts of proteins preventing macrophage clearance (like CD47, 'don't eat me' signal). Coating nanoparticles with red blood cell membranes can extend their circulation time from hours to days, greatly improving drug delivery efficiency.
NK cell membrane coating (NK-NP) — NK cells can naturally recognize and adhere to tumor cells (through activating receptors like NKG2D). Coating nanoparticles with NK cell membranes makes them inherit NK cells' tumor-targeting recognition capability, while carrying immune-activating or chemotherapy drugs, achieving 'NK cell-guided precision targeted delivery.' Tumor cell membrane coating (Tumor-NP) — coating nanoparticles with tumor cells' own membranes, with immune-activating adjuvants inside, after injection acting as a kind of 'individualized tumor vaccine,' presenting the complete tumor antigen profile to the immune system, activating broad-spectrum anti-tumor T cell responses.
5. Immune nanotechnology in autoimmune disease: targeting 'shut off' specific immune responses
Nanotechnology in immune medicine isn't only used for enhancing immunity (vaccines, cancer treatment) — it's also being explored for precision suppression of abnormal immune responses (autoimmune diseases). In autoimmune disease nano-immunotherapy, the goal is to induce 'antigen-specific immune tolerance' — teaching the immune system to 'ignore' specific self-antigens, rather than comprehensively suppressing the entire immune system (what traditional immunosuppressants do). Strategies showing promise in animal models: tolerogenic nanoparticles (Tolerogenic NP) — designing nanoparticles carrying self-antigens (like insulin peptide for type 1 diabetes, myelin peptide for multiple sclerosis) and immunosuppressive signals (like vitamin D receptor agonists, IL-2), targeting dendritic cells, promoting their presentation of self-antigens to T cells in 'tolerogenic' mode, inducing Treg cells, turning off immune attacks on this specific self-antigen.
Frequently Asked Questions